Telomir Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Telomir Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Telomir Pharmaceuticals Inc recorded a cumulative net loss of $-6 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -90.75%.

However, within the Healthcare sector 716 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4451, from total ROA ranking in the first quarter of 2026 at 5257.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	546.79 %	1078.69 %	454.48 %	610.39 %	-60.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-9	-10	-11	-16
Return On Assets (TTM)	-90.75 %	-172.72 %	-259.29 %	-445.52 %	-1744.47 %
TELO's Total Ranking	# 4451	# 5257	# 4729	# 4895	# 4937
Total Assets (TTM) in million	5	6	7	7	1
Seq. Total Assets Change	-7.32 %	-21.14 %	-0.82 %	792.23 %	68.9 %
Seq. Net Income Change	-	-	-	-	-

TELO's 5 Years Annual ROA >> Back to TELO Management Effectiveness >> Compare TELO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 329
Sector	# 717
Overall	# 4185

Return On Assets Statistics
High	Average	Low
-90.75 %	-649.62 %	-1744.48 %
(Jun 30 2026)		(Jun 30 2025)

Financial Statements
Telomir Pharmaceuticals Inc 's Assets	$ 5 million	TELO's Balance sheet
Telomir Pharmaceuticals Inc 's Income	$ -2 million	Quarterly TELO's Income Statement
TELO's Income by Division		See TELO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	454.48 %	-72.27 %	-	-	-
Total Assets in million	7	1	5	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-17	-13	0	0
Annual Return On Assets	-141.84 %	-1248.69 %	-273.83 %	-	-

TELO's 5 Years Annual ROA >> Back to TELO Management Effectiveness >> Compare TELO ROA to its Competitors

More Return On Assets Ratios
TELO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TELO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TELO's Competitors
Subscribers only: Roa for Telomir Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for TELO's Customers

You may also want to know
TELO's Roi	TELO's Inventory Turnover Ratio	TELO's Growth Rates	TELO's Dividend Comparisons
	TELO's Profitability Ratios	TELO's Asset Turnover Ratio	TELO's Dividend Growth
TELO's Roe	TELO's Valuation Ratios	TELO's Financial Strength Ratios	TELO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.